Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ebronucimab (AK102) in Primary Hypercholesterolemia and Mixed Hyperlipidemia
NCT05260411Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ebronucimab in hypercholesterolemia, mixed hyperlipidemia, sponsored by Akeso, Inc.. Started Jan 2022; status: completed.
02
Drugs
ebronucimab
03
Conditions
hypercholesterolemiamixed hyperlipidemia
Beyond the preview
Go deeper on NCT05260411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05260411.